An In-Depth Look at Biocryst Pharmaceuticals Inc.’s (BCRX) Stock Performance

The stock of Biocryst Pharmaceuticals Inc. (BCRX) has seen a 4.41% increase in the past week, with a -4.42% drop in the past month, and a 7.38% flourish in the past quarter. The volatility ratio for the week is 3.81%, and the volatility levels for the past 30 days are at 3.61% for BCRX. The simple moving average for the last 20 days is 0.44% for BCRX’s stock, with a simple moving average of 19.60% for the last 200 days.

Is It Worth Investing in Biocryst Pharmaceuticals Inc. (NASDAQ: BCRX) Right Now?

BCRX has 36-month beta value of 1.89. Analysts have mixed views on the stock, with 5 analysts rating it as a “buy,” 2 as “overweight,” 2 as “hold,” and 1 as “sell.”

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free
Sponsored

The public float for BCRX is 195.87M, and currently, short sellers hold a 11.86% ratio of that float. The average trading volume of BCRX on October 17, 2024 was 2.08M shares.

BCRX) stock’s latest price update

Biocryst Pharmaceuticals Inc. (NASDAQ: BCRX)’s stock price has soared by 1.20 in relation to previous closing price of 7.48. Nevertheless, the company has seen a gain of 4.41% in its stock price over the last five trading days. globenewswire.com reported 2024-10-14 that RESEARCH TRIANGLE PARK, N.C., Oct. 14, 2024 (GLOBE NEWSWIRE) — BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced new real-world evidence on the use of oral, once-daily ORLADEYO® (berotralstat) demonstrating that patients with hereditary angioedema (HAE) in the United States experience significant reductions in healthcare resource utilization (HRU), including significant reductions in hospitalizations, emergency room visits and use of on-demand therapies, after beginning treatment with ORLADEYO.

Analysts’ Opinion of BCRX

Many brokerage firms have already submitted their reports for BCRX stocks, with JP Morgan repeating the rating for BCRX by listing it as a “Overweight.” The predicted price for BCRX in the upcoming period, according to JP Morgan is $10 based on the research report published on November 20, 2023 of the previous year 2023.

RBC Capital Mkts, on the other hand, stated in their research note that they expect to see BCRX reach a price target of $10, previously predicting the price at $9. The rating they have provided for BCRX stocks is “Outperform” according to the report published on September 18th, 2023.

Jefferies gave a rating of “Buy” to BCRX, setting the target price at $11 in the report published on August 04th of the previous year.

BCRX Trading at -2.90% from the 50-Day Moving Average

After a stumble in the market that brought BCRX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -14.75% of loss for the given period.

Volatility was left at 3.61%, however, over the last 30 days, the volatility rate increased by 3.81%, as shares sank -4.90% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -3.81% lower at present.

During the last 5 trading sessions, BCRX rose by +4.41%, which changed the moving average for the period of 200-days by +26.38% in comparison to the 20-day moving average, which settled at $7.54. In addition, Biocryst Pharmaceuticals Inc. saw 26.38% in overturn over a single year, with a tendency to cut further gains.

Insider Trading

Reports are indicating that there were more than several insider trading activities at BCRX starting from McKee Amy E, who sale 8,600 shares at the price of $6.32 back on Jun 24 ’24. After this action, McKee Amy E now owns 27,831 shares of Biocryst Pharmaceuticals Inc., valued at $54,352 using the latest closing price.

SANDERS MACHELLE, the Director of Biocryst Pharmaceuticals Inc., sale 4,689 shares at $6.00 during a trade that took place back on Jun 17 ’24, which means that SANDERS MACHELLE is holding 27,742 shares at $28,134 based on the most recent closing price.

Stock Fundamentals for BCRX

Current profitability levels for the company are sitting at:

  • -0.16 for the present operating margin
  • 0.98 for the gross margin

The net margin for Biocryst Pharmaceuticals Inc. stands at -0.38. The total capital return value is set at -0.18.

Based on Biocryst Pharmaceuticals Inc. (BCRX), the company’s capital structure generated 2.3 points at debt to capital in total, while cash flow to debt ratio is standing at -0.1. The debt to equity ratio resting at -1.77. The interest coverage ratio of the stock is -0.59.

Currently, EBITDA for the company is -102.05 million with net debt to EBITDA at -15.09. When we switch over and look at the enterprise to sales, we see a ratio of 6.11. The receivables turnover for the company is 5.56for trailing twelve months and the total asset turnover is 0.81. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.82.

Conclusion

To put it simply, Biocryst Pharmaceuticals Inc. (BCRX) has had a better performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.

Related Posts